1. Agreement of expert judgment in causality assessment of adverse drug reactions

   • Yannick Arimone
   • Bernard Bégaud
   • Françoise Haramburu

   Review Article 13 April 2005 Pages: 169 - 173

   

2. Interaction between mivacurium and pancuronium: impact of the order of administration

   • C. Motamed
   • K. Kirov
   • P. Duvaldestin

   Pharmacodynamics 12 April 2005 Pages: 175 - 177

3. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study

   • Heydy V. Bravo-Villalta
   • Koujirou Yamamoto
   • Ryuya Horiuchi

   Pharmacogenetics 18 March 2005 Pages: 179 - 184

4. Induction of the metabolism of etizolam by carbamazepine in humans

   • S. Kondo
   • T. Fukasawa
   • K. Otani

   Pharmacokinetics and Disposition 18 March 2005 Pages: 185 - 188

   

5. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin

   • Anargyros Xenocostas
   • Wing K. Cheung
   • Hans A. Messner

   Pharmacokinetics and Disposition 18 March 2005 Pages: 189 - 195

   

6. Influence of cigarette smoking on melatonin levels in man

   • Carina Ursing
   • Christer von Bahr
   • Sven Röjdmark

   Pharmacokinetics and Disposition 12 April 2005 Pages: 197 - 201

   

7. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects

   • Ruediger Nave
   • Karl Zech
   • Thomas D. Bethke

   Pharmacokinetics and Disposition 12 April 2005 Pages: 203 - 208

   

8. Treatment with angiotensin converting enzyme inhibitors, angiotensin-II-antagonists and beta-blockers in an unselected group of patients with chronic heart failure

   • Ragnar Watz
   • Ann-Britt Ekstrand
   • Björn Beermann

   Pharmacoepidemiology and Prescription 11 March 2005 Pages: 209 - 214

   

9. Perceived anxiety, depression, and sleeping problems in relation to psychotropic drug use among elderly in assisted-living facilities

   • Ing-Britt Holmquist
   • Bengt Svensson
   • Peter Höglund

   Pharmacoepidemiology and Prescription 11 March 2005 Pages: 215 - 224

10. Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy

    • Mirko Di Martino
    • Luca Degli Esposti
    • Ezio Degli Esposti

    Pharmacoepidemiology and Prescription 12 April 2005 Pages: 225 - 230

    

11. Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study

    • A. P. Jonville-Béra
    • F. Béra
    • E. Autret-Leca

    Pharmacoepidemiology and Prescription 12 April 2005 Pages: 231 - 236

12. General practitioners prefer prescribing indicators based on detailed information on individual patients: a Delphi study

    • Hanne MS Rasmussen
    • Jens Søndergaard
    • Morten Andersen

    Pharmacoepidemiology and Prescription 27 April 2005 Pages: 237 - 241

13. Changes in the defined daily dose; CYP2D6/CYP3A metabolism as an indicator for dose-setting problems

    • P. Stolk
    • E. R. Heerdink
    • H. G. M. Leufkens

    Pharmacoepidemiology and Prescription 28 April 2005 Pages: 243 - 246